What drove McKesson's revenue growth in Q2 2025?

McKesson's revenue growth in Q2 2025 was driven by several key factors:

1. **Increase in Prescription Volumes**: The U.S. Pharmaceutical segment experienced a significant increase in revenue, driven by higher prescription volumes. This was partly due to the introduction of new strategic partners and heightened demand for specialty products, including GLP-1 medications.
2. **Strategic Partnerships and Oncology Platform Growth**: The company's oncology platform expansion and strategic partnerships contributed to the growth. The US Oncology Network and strategic acquisitions in the oncology sector likely played a role in the revenue increase.
3. **International Segment Growth**: The International Segment Revenue increased by 7% year-over-year, contributing to the overall revenue growth.
4. **Technological Advancements**: Investments in technology and modernization initiatives are expected to generate significant benefits over the next five years, indicating a focus on innovation that can drive future growth.

In summary, McKesson's revenue growth in Q2 2025 was driven by a combination of increased prescription volumes, strategic partnerships, growth in the oncology segment, and international segment growth, along with technological advancements that are poised to enhance future performance.